We believe that after the fatal clinical trial in 1999 in which a patient suffering from ornithine transcarbamylase deficiency died after systemic administration of an early generation adenoviral vector45,46, this type of vector is unlikely to be approved for clinical trials in the future; especially for treatment of non-cancerous diseases. The gene discussed is OTC; the disease is glycogen storage disease VI.